[P3–032]: SSRI USE ASSOCIATED WITH REDUCED AMYLOID BURDEN IN PERSONS WITH COMBAT‐RELATED PTSD: PRELIMINARY FINDINGS FROM ADNI‐DOD

Dhruman D. Goradia,Kewei Chen,Yinghua Chen,Noelle Snyder,Danielle Harvey,Susan M. Landau,William J. Jagust,Michael Weiner,Eric M. Reiman

DOI: https://doi.org/10.1016/j.jalz.2017.06.1845

2017-01-01

Abstract:Sheline et al. (2014) suggested that selective serotonin reuptake inhibitors (SSRI) may be associated with reduced amyloid plaque burden. SSRIs are commonly used in the treatment of posttraumatic stress disorder (PTSD). Using data from the ADNI-DOD study, we previously demonstrated that, compared to normal controls, older adults with combat-related PTSD had lower amyloid plaque burden, computed as the cerebral-to-cerebellar standard uptake value ratio (SUVR), and a smaller proportion of amyloid positive cases based on florbetapir PET measurements, suggesting that the reduction in amyloid burden was partly attributable to their use of SSRI and other antidepressants. In this study, we directly evaluated the impact of SSRI use on amyloid burden in PTSD participants from ADNI-DOD. As an omnibus approach, we used the Monte Carlo simulation procedure to compute the global type-I error that the number of voxels with lower SUVR in the SSRI treated PTSD participants is higher than the number of voxels in the opposite direction (lower SUVR in the non-treated PTSD participants). An automated brain mapping algorithm was used to generate a brain map of mean gray matter SUVR differences between 16 PTSD participants treated with SSRI (68.6±4.5 years) and 27 PTSD participants who were not treated with SSRI (67.7±3.7 years). We computed the number of cerebral gray matter voxels associated with lower versus higher mean SUVRs in the SSRI treated versus non-treated groups, controlled for effects of age, education, APOE4 carrier status, MMSE scores and depression ratings, and used 1000 Monte Carlo simulations to assess the type-I error of finding the higher proportion of voxels with lower than higher SUVRs in the SSRI groups. In comparison with non-users, SSRI users had 55 times more cerebral voxels with lower than higher mean SUVR (13536 versus 245 voxels, Pmc<0.001). Consistently, the chi-square test showed that the proportion of lower than higher mean SUVR in SSRI treated group was significant (p<0.01). This study provides additional support for the possibility that SSRI use is associated with reduced amyloid plaque burden. Additional studies are needed to confirm our findings and further clarify their generalizability to other populations.